Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A.

Human molecular genetics - 1 Nov 2013

Yamauchi Jenny, Kumar Ajay, Duarte Lina, Mehuron Thomas, Girgenrath Mahasweta

Abstract excerpt

Merosin-deficient congenital muscular dystrophy type 1A (MDC1A) is an autosomal recessive disorder caused by mutations in the laminin-α2 gene (OMIM: 607855). Currently, no treatment other than palliative care exists for this disease. In our previous work, genetic interventions in the Lama2(Dy-w) mouse model for MDC1A demonstrated that limited regeneration and uncontrolled apoptosis are important drivers of this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-2-Associated X Protein
Share to Insulin-Like Growth Factor Binding Protein 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Insulin-Like Growth Factor I

Share to Lamin Type A

Share to Laminin

Share to Muscular Dystrophies

Share to Muscular Dystrophy, Animal

Share to Regeneration

Source

Identifiers

PMID: 23773998
DOI: 10.1093/hmg/ddt280

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A.PMID 23773998Read ↗

Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy.Semantic proximity Read ↗

Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1ASemantic proximity Read ↗

IGF-1/GH axis enhances losartan treatment in Lama2-related muscular dystrophySemantic proximity Read ↗

Laminin-α2 Chain-Deficient Congenital Muscular Dystrophy: Pathophysiology and Development of Treatment.Semantic proximity Read ↗

Lama1 upregulation prolongs the lifespan of the dyH/dyH mouse model of LAMA2-related congenital muscular dystrophy.Semantic proximity Read ↗

Early skeletal muscle pathology and disease progress in the dy3K/dy3K mouse model of congenital muscular dystrophy with laminin α2 chain-deficiencySemantic proximity Read ↗

Laminin-111 Protein Therapy Reduces Muscle Pathology and Improves Viability of a Mouse Model of Merosin-Deficient Congenital Muscular DystrophySemantic proximity Read ↗

Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy.Semantic proximity Read ↗

Laminin-α2 chain deficiency in skeletal muscle causes dysregulation of multiple cellular mechanisms.Semantic proximity Read ↗

Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis.Semantic proximity Read ↗

Pharmacological PIK3C2B inhibition rescues XLMTM phenotype in mouse models and identifies molecular markers of disease.Semantic proximity Read ↗

Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.